Abstract
High triglyceride in a serum sample with no apparent visible lipaemia is a confusing laboratory condition. This condition of apparent hypertriglyceridaemia might be an asymptomatic condition of pseudo-hypertriglyceridaemia which is seen in individuals with glycerol kinase deficiency. Glycerol is increased in glycerol kinase deficiency, therefore biochemical analysers that measure glycerol to estimate triglyceride report high triglyceride values. Clinicians are often unaware of this laboratory condition; as a result, patients are subjected to aggressive hypolipidaemic drugs and lifestyle changes, and these measures turn ineffective to lower triglyceride levels. In this report, a case of a 50-year-old Nepalese male is presented with an apparent hypertriglyceridaemia refractory to various hypolipidaemic drugs for the last 13 years until a correct diagnosis of his condition was made.
Keywords: lipid disorders, genetic screening/counselling, pathology
Background
Pseudohypertriglyceridaemia seen in glycerol kinase deficiency (GKD) is biochemically characterised by the presence of hyperglycerolaemia and glyceroluria. This X-linked recessive disorder is frequently misdiagnosed as true hypertriglyceridaemia and is often recognised after unsuccessful attempts to treat hypertriglyceridaemia.1 The apparent hypertriglyceridaemia in this condition is due to the measurement of glycerol to report triglyceride by the biochemical assays.2 Three fatty acids are attached to one glycerol backbone to form a triglyceride and this is utilised by the manufacturer to develop assays that can measure glycerol to report triglyceride.3 Free glycerol in the serum sample is acted on by a specific lipase that initiates a series of reactions to form a measurable product that corresponds to the amount of triglyceride in a given sample (figure 1). The major disadvantage of this universal method is that it also measures endogenous free glycerol though it is usually very less in concentration (about 1.8 mg/dL).4
Figure 1.
Triglyceride measurement in a clinical laboratory (created by Dr Vivek Pant). GKD, glycerol kinase deficiency.
This report emphasises that the laboratory personnel should indicate whether the analysed sample was lipaemic according to the degree of hypertriglyceridaemia. Furthermore, clinicians need to be aware of this rare disease and should consider a consultation with the laboratory personnel in any event of hypertriglyceridaemia irresponsive to treatment.
Case presentation
A 50-year-old male visited our clinical laboratory with his laboratory reports for counselling about his persistent high triglyceride despite aggressive medical treatment and lifestyle change. Since 13 years, he had moderate hypertriglyceridaemia but total cholesterol and low density lipoprotein (LDL) cholesterol were within the normal range. He had no history of any comorbid conditions and the use of any medication. There was an absence of xanthoma and corneal arcus. His serum triglyceride level was in the range of 600–900 mg/dL before the initiation of treatment. He had been treated with multiple triglyceride-lowering drugs and has been physically active with strict dietary control. On inquiring about his symptoms, he complained of feeling tired and lethargic when fasting for a prolonged duration of time. However, blood glucose level monitoring and other relevant investigations were never done for these complaints. Whenever he took red meat or a glass of wine, the triglyceride level suddenly went above 500 mg/dL despite using his regular medication for hypertriglyceridaemia. He never had a serum triglyceride level below 400 mg/dL in recent years, but he continued to exercise and abstained from high-calorie diet.
He was worried about his persistent hypertriglyceridaemia despite all known medical treatments for 13 years (figure 2). However, on follow- up consultation, physicians kept questioning him about the compliance with the prescribed medicines, and he grew more and more despondent.
Figure 2.
Serum triglyceride results along with medical treatment given to the patient in the last 13 years.
We considered repeating his blood test for serum triglyceride. We advised him to refrain from all possible diets that increase triglyceride, continue his hypolipidaemic drugs and asked him to fast for 12 hours. On the following day, his serum triglyceride was 550 mg/dL at our laboratory. Incongruent to the serum finding, when we inspected his serum sample, the sample was clear. Had it been a true triglyceride level of 550 mg/dL, it would have blurred the background behind the specimen tube (figure 3).
Figure 3.
Comparison of patient’s serum sample with other true hypertriglyceridaemic serum samples.
We retested the serum triglyceride level in different assay platforms, and the results were similar.
Therefore, we suspected that the index case of hypertriglyceridaemia with visibly clear serum could be a case of pseudohypertriglyceridaemia.
Investigations
Pseudohypertriglyceridaemia or hyperglycerolaemia is suspected whenever there is an absence of a response from triglyceride-lowering therapies, in cases of moderate long-standing hypertriglyceridaemia. The quantification of free glycerol in serum and urine of the suspected case confirms the diagnosis of pseudohypertriglyceridaemia.
Any elevated free glycerol in serum can be measured in the urine using the similar technique used for triglyceride assay. Since the renal threshold for glycerol is very low, one expects urinary triglyceride values in 100 mg/dL and higher. Triglyceride concentration in the patient’s urine sample was 2534 mg/dL (reference range=undetectable), thereby indicating the presence of glyceroluria. Knowing that 10 mg/dL triglyceride roughly corresponds to only 1 mg/dL glycerol, this value corresponds to a high glycerol concentration in plasma which is not considered physiological.
The fasting serum glucose and insulin level, measured in the patient sample, was 90 mg/dL (70–100 mg/dL) and 24.2 µIU/mL (3–25 µIU/mL) which was normal.
As the most common cause of pseudohypertriglyceridaemia is an X-linked recessive GKD disorder, we performed clinical whole- genome sequencing to identify the cause.
In clinical genome sequencing, a hemizygous single base pair deletion in exon 2 of the glycerol kinase gene (chrX: g.30683687delG; Depth: 47x) that results in a frameshift and premature truncation of the protein 23 amino acids downstream to codon 46 (p.Glu46AspfsTer23; ENST00000378943.3) was detected (table 1). The review of the ClinVar dataset shows that there are no previous reports of this genetic variant for GKD.5 The in silico prediction of the variant was damaging by Mutation Taster 2. The reference region is conserved across mammals.
Table 1.
Report of clinical genome sequencing :pathogenic variant of glycerol kinase deficiency
| Gene (transcript) | Location | Variant | Zygosity | Disease | Inheritance | Classification |
| GK (+) (ENST00000378943.3) |
Exon 2 | c.138delG (p.Glu46AspfsTer23 |
Hemizygous | Glycerol kinase deficiency | X-linked recessive | Pathogenic |
Differential diagnosis
Differential diagnoses of hyperglycerolaemia such as critical illness, chronic alcoholism, and hyperthyroidism were not present or ruled out in our patient.
Treatment
Owing to the genetic diagnosis of GKD, the increased triglyceride in the index case was labelled as pseudohypertriglyceridaemia, and lipid-lowering treatment was discontinued.
On reviewing family history in this case, we found that his younger brother also had persistent hypertriglyceridaemia unresponsive to multiple treatments. Therefore, sequencing the variant in his brother was recommended to confirm the significance.
Outcome and follow-up
Because the LDL cholesterol was normal when estimated by direct method, all the hypolipidaemic drugs that the patient was using were discontinued. He was advised to maintain his modified lifestyle for the added benefit of cardiovascular risk reduction and weight maintenance. He is under regular follow-up at our institution and is doing well.
Discussion
GKD, an X-linked recessive enzyme disorder, can be clinically distinguished as an isolated disorder or a disorder complexed with conditions such as congenital adrenal hypoplasia or Duchenne muscular dystrophy, according to the locus involved.6 There was no clinical evidence of the presence of a complex form of GKD in the index case.
Hyperglycerolaemia seen in isolated GKD could be manifested in children as an acute metabolic crisis whereas, in adults, it could be asymptomatic. However, the asymptomatic form in adults may be associated with glucose impairment. The identification of such a benign adult form is important for two reasons. First, to avoid unnecessary interventions related to pseudohypertriglyceridaemia, and, second, to preinform the affected families about the increased risk for symptomatic GKD in male babies. Bakes et al defined the clinical characteristics of patients with a benign form of GKD or pseudohypertriglyceridaemia as male gender, elevated triglyceride values less than 1000 mg/dL, visibly clear serum sample, refractory to triglyceride-lowering therapies, impaired glucose homeostasis and absence of features suggesting other metabolic syndromes.7 All these characteristics were present in the patient described in this report.
The deficiency of glycerol kinase enzyme in GKD results in elevated glycerol and free fatty acids (FFAs). Consequently, more glycerol enters the gluconeogenesis pathway causing impaired glucose metabolism and predisposition to type 2 diabetes mellitus. Likewise, an increase in FFA enhances glucose production from the liver and insulin release from the pancreas, which may cause intermittent hypoglycaemia. The index case had clinical features of intermittent fasting hypoglycaemia though it was not evaluated in the past. The real-time PCR analysis has confirmed that the glycerol kinase activity is linked to genes of major metabolic pathways such as carbohydrate and lipid metabolism and insulin signalling and resistance.8
The biochemical assays utilise specific lipases to de-esterify the three fatty acids from the glycerol backbone of triglyceride and measures glycerol to report triglyceride in a given sample.3 Individuals with GKD have hyperglycerolaemia; thus, false reporting of higher triglyceride values is frequently seen in this condition (figure 1). To overcome such false reporting, the interference from endogenous glycerol could be avoided by the use of the ‘glycerol blanking’ approach. In this approach, the free glycerol in a given sample is first consumed by the use of specific enzymes. However, this consumption does not elicit any chromogen formation or absorption change. Thereafter, the remaining triglyceride in a sample is measured as usual by the addition of lipase and additional enzymes. However, the glycerol blanking test is only available in a few specialised laboratories in the world. Therefore, the surrogate measures to support the diagnosis of pseudohypertriglyceridaemia are blood and urine glycerol concentrations analysis. The biological reference range for serum glycerol does not exceed 1.8 mg/dL, while the level of glycerol in urine is negligible. Any elevated free glycerol in the blood can easily be measured in the urine by employing the same principle of plasma triglyceride measurement. In GKD, urinary triglyceride value is highly raised, since the renal threshold for glycerol is very low. This investigation is particularly important in the resource settings where the glycerol blanking test or genetic analysis could not be done.
The index patient was prescribed a combination of hypolipidaemic drugs such as statins, fibrates, omega- 3 fatty acid and nicotinic acid. There is an increased risk for myopathy and rhabdomyolysis with the use of a statin–fibrate combination.9 However, no such event was recorded for the index case.
The present case shows that the artefact of measurement could lead to false reporting of triglyceride in the case of GKD. The clinicians need to be aware of this condition and could benefit from communicating with laboratory personnel whenever they encounter cases of hypertriglyceridaemia refractory to treatment.
Learning points.
Isolated glycerol kinase deficiency or pseudohypertriglyceridaemia is a rare disease characterised by artefactual elevation of plasma triglycerides.
Absence of the expected visible turbidity in the serum sample discordant with the reported serum triglyceride value is a clue to pseudohypertriglyceridaemia.
The standard glycerol blanking test is not easily available, therefore the present case underlines the usefulness of determining triglyceride concentrations in urine as a screening test for hyperglycerolaemia because triglycerides are not excreted by the kidney, even in true severe hypertriglyceridaemia.
Diagnosis of asymptomatic GKD is important to prevent iatrogenic effects from triglyceride-lowering drugs and to make the affected families aware of the increased risk for the symptomatic form of this disease in male babies.
Acknowledgments
None.
Footnotes
Contributors: VP conceived the study and wrote the manuscript. SP, DP and KG reviewed the literature and provided the scientific content for the study. All authors provided critical revision of the draft and approved the submitted draft.
Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.
Competing interests: None declared.
Provenance and peer review: Not commissioned; externally peer reviewed.
Ethics statements
Patient consent for publication
Consent obtained directly from patient(s).
References
- 1.Sjarif DR, Ploos van Amstel JK, Duran M, et al. Isolated and contiguous glycerol kinase gene disorders: a review. J Inherit Metab Dis 2000;23:529–47. 10.1023/A:1005660826652 [DOI] [PubMed] [Google Scholar]
- 2.Cole TG. Glycerol blanking in triglyceride assays: is it necessary? Clin Chem 1990;36:1267–8. 10.1093/clinchem/36.7.1267 [DOI] [PubMed] [Google Scholar]
- 3.Richterich R. Triglycerides: enzymatic determination as glycerol. Clin Chem 1969:274–8. [Google Scholar]
- 4.Wibmer T, Otto J, Parhofer KG, et al. Novel mutation (Gly280Ala) in the ATP-binding domain of glycerol kinase causes severe hyperglycerolemia. Exp Clin Endocrinol Diabetes 2005;113:396–403. 10.1055/s-2005-865723 [DOI] [PubMed] [Google Scholar]
- 5.National center for biotechnology information. ClinVar. Available: https://www.ncbi.nlm.nih.gov/clinvar/ [Accessed 10 Oct 2021].
- 6.Cole DE, Clarke LA, Riddell DC, et al. Congenital adrenal hypoplasia, Duchenne muscular dystrophy, and glycerol kinase deficiency: importance of laboratory investigations in delineating a contiguous gene deletion syndrome. Clin Chem 1994;40:2099–103. 10.1093/clinchem/40.11.2099 [DOI] [PubMed] [Google Scholar]
- 7.Backes JM, Dayspring TD, Hoefner DM, et al. Identifying pseudohypertriglyceridemia in clinical practice. Clin Lipidol 2014;9:625–41. 10.2217/clp.14.52 [DOI] [Google Scholar]
- 8.Rahib L, MacLennan NK, Horvath S, et al. Glycerol kinase deficiency alters expression of genes involved in lipid metabolism, carbohydrate metabolism, and insulin signaling. Eur J Hum Genet 2007;15:646–57. 10.1038/sj.ejhg.5201801 [DOI] [PubMed] [Google Scholar]
- 9.Shek A, Ferrill MJ. Statin—Fibrate combination therapy. Ann Pharmacother 2001;35:908–17. 10.1345/aph.10315 [DOI] [PubMed] [Google Scholar]



